Right drug for the right patient

It is estimated that 30% of treatments in late-stage clinical development rely upon biomarker data and that perhaps as many as 70% of all treatments currently in development have an associated companion diagnostic test. Turn on the television and you may even see an advertisement from companies such as 23andMe offering a kit to provide genotype information on different health conditions and traits for little more than £125 (it costs $99 in the US).